Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer
- 798 Downloads
Platinum-based chemotherapy is the treatment of choice for malignant epithelial ovarian cancers, but generalized toxicity and platinum resistance limits its use. Theranostic nanoemulsion with a novel platinum prodrug, myrisplatin, and the pro-apoptotic agent, C6-ceramide, were designed to overcome these limitations.
The nanoemulsions, including ones with an EGFR binding peptide and gadolinium, were made using generally regarded as safe grade excipients and a high shear microfluidization process. Efficacy was evaluated in ovarian cancer cells, SKOV3, A2780 and A2780CP.
The nanoemulsion with particle size <150 nm were stable in plasma and parenteral fluids for 24 h. Ovarian cancer cells in vitro efficiently took up the non-targeted and EGFR-targeted nanoemulsions; improved cytotoxicity was observed for the these nanoemulsions with the latter showing a 50-fold drop in the IC50 in SKOV3 cells as compared to cisplatin alone. The addition of gadolinium did not affect cell viability in vitro, but showed relaxation times comparable to Magnevist®.
The myrisplatin/C6-ceramide nanoemulsion synergistically enhanced in vitro cytotoxicity. An EGFR binding peptide addition further increased in vitro cytotoxicity in EGFR positive cancer cells. The diagnostic version showed MR imaging similar to the clinically relevant Magnevist® and may be suitable as a theranostic for ovarian cancer.
KEY WORDSC6-ceramide EGFR gadolinium MRI nanoemulsion ovarian cancer platinum
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by the NIH grants (R43 CA144591 and U54 CA151881). Joseph Cacaccio and Yashesh Rawal received financial support from the Massachusetts Life Science Center Internship Challenge. Additionally, the authors thank Nanotechnology Characterization Lab (Fredrick, MD) for Pt analysis and Drs. Praveen Kulakarni and Craig Ferris in the Center for Translational Neuro-Imaging at Northeastern University (Boston, MA) for help with the MRI studies.
- 8.Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA, et al. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res. 2012;29(10):2874–86.PubMedCrossRefGoogle Scholar
- 12.Ganta S, Devalapally H, Baguley BC, Garg S, Amiji M. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol. 2008;4(2):165–73.Google Scholar
- 16.Maeda M, Sasaki T, inventors; Sumitomo Pharmaceuticals Company Ltd, assignee. Liposoluble platinum (II) complex and preparation thereof. US 6,613,799 B1; 2003.Google Scholar
- 18.Tiwari S, Tan YM, Amiji M. Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery. J Biomed Nanotechnol. 2006;2(3–4):3–4.Google Scholar
- 20.Clogston JD, Patri AK. Detecting and measuring free gadolinium in nanoparticles for MRI imaging. In: McNeil SE, editor. Methods in Molecular Biology: Characterization of nanoparticles intended for drug delivery. New York: Human Press; 2011. p. 101–8.Google Scholar
- 33.Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99(2):415–21.PubMedCrossRefGoogle Scholar
- 38.Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, et al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011;2:e117.PubMedCrossRefPubMedCentralGoogle Scholar